Valsts: Īrija
Valoda: angļu
Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)
Furosemide
Fresenius Kabi Deutschland GmbH
C03CA; C03CA01
Furosemide
20 mg/2ml
Solution for injection
Sulfonamides, plain; furosemide
Not marketed
2008-02-01
UK-IE PIL Furosemide V006 PACKAGE LEAFLET: INFORMATION FOR THE USER Furosemide 20mg/2ml solution for injection/infusion furosemide furosemide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Furosemide is and what it is used for 2. What you need to know before you use Furosemide 3. How to use Furosemide 4. Possible side effects 5. How to store Furosemide 6. Contents of the pack and other information 1. WHAT FUROSEMIDE IS AND WHAT IT IS USED FOR Furosemide belongs to a group of medicines called diuretics. Furosemide increases the amount of urine produced by your body. Furosemide is used to relieve symptoms caused when your body contains too much fluid (also called oedema). Too much fluid can be caused by: • heart problems • liver problems • kidney problems Your doctor has prescribed Furosemide for one of the following reasons: • When quick and effective removal of excess fluid is needed. • You are not able to take this kind of medicine by mouth or in an emergency. • You have too much fluid around your heart, lungs, liver or kidneys. In periods with extremely high blood pressure that may lead to life-threatening conditions (hypertensive crisis). 2. WHAT YOU NEED TO KNOW BEFORE YOU USE FUROSEMIDE DO NOT USE FUROSEMIDE ▪ if you are allergic to furosemide, or any of the other ingredients of this medicine (listed in section 6) ▪ if you are allergic to sulphonamide antibiotics ▪ if you are severely dehydrated (you have lost lots of body fluid for example by suffering from severe diarrhoe Izlasiet visu dokumentu
Health Products Regulatory Authority 03 November 2023 CRN00DDZX Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Furosemide 20 mg/2 ml solution for injection/infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2 ml ampoule contains 20 mg of furosemide corresponding to 10 mg furosemideper ml. Excipient with known effect: This medicinal product contains 3.7 mg sodium per ml. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Solution for injection/infusion. Clear, colourless to almost colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - Oedema and/or ascitescaused by cardiac or hepatic diseases - Oedema caused by renal diseases (in case of nephroticsyndrome, treatment of the underlying disease is essential) - Pulmonaryoedema (e.g. in case of acute heart failure) - Hypertensivecrisis (in addition to other therapeutic measures) The parenteral administration of furosemide is indicated for use incases where a prompt and effective diuresis is required or oral administrationis not feasible or not efficient. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology: The lowest dose with which the desired effect is achieved should always be used. The duration of the treatment should be determined by the doctor and be appropriate to the type and severity of the disease. The parenteral administration of furosemide is indicated in cases where oral administration is not feasible or not efficient (for example in case of reduced intestinal absorption) or when a quick effect is required. In cases where parenteral administration is used, the switch to oral administration is recommended, as soon as possible. To achieve optimum efficacy and suppress counter-regulation, a continuous furosemide infusion is generally to be preferred to repeated bolus injections. Where continuous furosemide infusion is not feasible for follow-up treatment after one or several acute bolus doses, a follow-up regimen with low doses given at short intervals (approx. 4 hours) is to be pref Izlasiet visu dokumentu